Cargando…
Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients
Cystinosis is a severe inherited metabolic storage disease caused by the lysosomal accumulation of cystine. Lifelong therapy with the drug cysteamine bitartrate is necessary. Cysteamine cleaves intralysosomal cystine, and thereafter, it can exit from the organelle. The need for frequent dosing every...
Autores principales: | Klank, Sabrina, van Stein, Christina, Grüneberg, Marianne, Ottolenghi, Chris, Rauwolf, Kerstin K., Grebe, Jürgen, Reunert, Janine, Harms, Erik, Marquardt, Thorsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385520/ https://www.ncbi.nlm.nih.gov/pubmed/37514038 http://dx.doi.org/10.3390/pharmaceutics15071851 |
Ejemplares similares
-
A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis
por: van Stein, Christina, et al.
Publicado: (2021) -
Cystinosis: Therapy adherence and metabolic monitoring in patients treated with immediate-release cysteamine
por: Linden, Simone, et al.
Publicado: (2020) -
A novel sustained‐release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers
por: Berends, Cécile L., et al.
Publicado: (2021) -
Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to “A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis”)
por: Langman, Craig B.
Publicado: (2023) -
Quality of Life is Improved and Kidney Function Preserved in Patients with Nephropathic Cystinosis Treated for 2 Years with Delayed-Release Cysteamine Bitartrate
por: Langman, Craig B., et al.
Publicado: (2014)